Förvaltningsresultat sjönk med drygt 6% på årsbasis drivet av en högre genomsnittlig räntenivå.
Aspo expands its operations in Sweden by acquiring Swed Handling.
Redeye is positive to the new revenue estimates presented by Fragbite Group for its wholly-owned sub...
Q-linea has secured a US FDA approval, which is positive.
Redeye has updated its estimates for Carasent following the Q1 2024 report, which was more or less i...
Redeye comments on Nitro Games' Q1 2024 report, which met expectations in terms of sales, while marg...
Svag start på året Efter en rekordstark avslutning på 2023 inleddes 2024 svagt.
Q1(24) i korthet Nettoomsättningen under Q1(24) uppgick till 9 mkr (13) och rörelseresultatet uppgic...
Q2 visar operativ styrka och hög aktivitet Hyresintäkterna ökade med 7% till 168 mkr (154) samtidigt...
Redeye offers an update on Advenica following the company's Q1 report.
Redeye is again making some upward revisions to our forecasts, on the back of solid Q1 numbers and a...
Full-year revenue and EBIDA guidance from the company remains intact but we lower our 2024 EBITDA fo...
Carlsquare Equity Research presenterar sina första intryck av Enrads kv1 2024-rapport.
Redeye retains its optimistic view on Hexatronic despite slightly lowering its Base Case and short-t...
Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a soft ...
Adj. EBITA in line, we expect higher margins ahead Minor revisions: adj.
Highest order intake in company's history We lift '24e-'26e EBIT by 14% on higher sales and GMs EBIT...
Redeye repeats its view on Sedana Medical’s 2024 sales growth target to be conservative, as is demon...
- Gross margin est. down on continually elevated freight rates - '24e-'26e EBITA down 4-2% - '24e-'2...
- '24e sales up 2% - New ARR shows sequential growth stability - '24e-'25e EV/EBITDA ~11-9x Another ...
